LY-CoV555, a rapidly isolated potent neutralizing antibody, provides protection in a non-human primate model of SARS-CoV-2 infection
By
Bryan E. Jones,
Patricia L. Brown-Augsburger,
Kizzmekia S. Corbett,
Kathryn Westendorf,
Julian Davies,
Thomas P. Cujec,
Christopher M. Wiethoff,
Jamie L. Blackbourne,
Beverly A. Heinz,
Denisa Foster,
Richard E. Higgs,
Deepa Balasubramaniam,
Lingshu Wang,
Roza Bidshahri,
Lucas Kraft,
Yuri Hwang,
Stefanie Žentelis,
Kevin R. Jepson,
Rodrigo Goya,
Maia A. Smith,
David W Collins,
Samuel J. Hinshaw,
Sean A. Tycho,
Davide Pellacani,
Ping Xiang,
Krithika Muthuraman,
Solmaz Sobhanifar,
Marissa H. Piper,
Franz J. Triana,
Jorg Hendle,
Anna Pustilnik,
Andrew C. Adams,
Shawn J. Berens,
Ralph S. Baric,
David R. Martinez,
Robert W Cross,
Thomas W Geisbert,
Viktoriya Borisevich,
Olubukola Abiona,
Hayley M. Belli,
Maren de Vries,
Adil Mohamed,
Meike Dittmann,
Marie Samanovic,
Mark J Mulligan,
Jory A Goldsmith,
Ching-Lin Hsieh,
Nicole V Johnson,
Daniel Wrapp,
Jason S McLellan,
Bryan C. Barnhart,
Barney S. Graham,
John R Mascola,
Carl L. Hansen,
Ester Falconer
Posted 01 Oct 2020
bioRxiv DOI: 10.1101/2020.09.30.318972
(published DOI: 10.1126/scitranslmed.abf1906)
SARS-CoV-2 poses a public health threat for which therapeutic agents are urgently needed. Herein, we report that high-throughput microfluidic screening of antigen-specific B-cells led to the identification of LY-CoV555, a potent anti-spike neutralizing antibody from a convalescent COVID-19 patient. Biochemical, structural, and functional characterization revealed high-affinity binding to the receptor-binding domain, ACE2 binding inhibition, and potent neutralizing activity. In a rhesus macaque challenge model, prophylaxis doses as low as 2.5 mg/kg reduced viral replication in the upper and lower respiratory tract. These data demonstrate that high-throughput screening can lead to the identification of a potent antiviral antibody that protects against SARS-CoV-2 infection. ### Competing Interest Statement M.J.M. has research grant funding from NIH/NIAID, Pfizer, and Sanofi; and personal fees from Meissa Vaccines, Inc. B.E.J., P.LB., J.D., T.P.C., C.M.W., J.L.B., B.A.H., R.E.H., D.B., D.F., M.H.P., F.J.T., J.H., A.P., A.C.A. and S.J.B. are employees and stockholders of Eli Lilly and Company. K.W., R.B., L.K., S.J.H., S.S., B.C.B, and E.F. are employees of AbCellera Biologics Inc. C.L.H., R.G., D.P., P.X., Y.H., R.B., K.R.J. M.A.S., S.Z., D.W.C., and S.A.T. are employees and stockholders of AbCellera Biologics Inc.. K.M. is a former employee and stockholder of AbCellera Biologics Inc. M.D. received a contract from Eli Lilly and Company to support the studies reported herein. Authors from AbCellera Biologics Inc., National Institute of Allergy and Infectious Diseases (K.S.C., B.S.G., and J.R.M.), and Eli Lilly and Company are inventors on patent applications related to the work described here. R.S.B., D.R.M., R.W.C., T.W.G, V.B., O.A., L.W., H.M.B., M.D.V., A.D., M.S., J.A.G., C.L.H., N.V.J., J.S.M., and D.W. declare no competing interests.
Download data
- Downloaded 6,273 times
- Download rankings, all-time:
- Site-wide: 1,444
- In immunology: 33
- Year to date:
- Site-wide: 369
- Since beginning of last month:
- Site-wide: 506
Altmetric data
Downloads over time
Distribution of downloads per paper, site-wide
PanLingua
News
- 27 Nov 2020: The website and API now include results pulled from medRxiv as well as bioRxiv.
- 18 Dec 2019: We're pleased to announce PanLingua, a new tool that enables you to search for machine-translated bioRxiv preprints using more than 100 different languages.
- 21 May 2019: PLOS Biology has published a community page about Rxivist.org and its design.
- 10 May 2019: The paper analyzing the Rxivist dataset has been published at eLife.
- 1 Mar 2019: We now have summary statistics about bioRxiv downloads and submissions.
- 8 Feb 2019: Data from Altmetric is now available on the Rxivist details page for every preprint. Look for the "donut" under the download metrics.
- 30 Jan 2019: preLights has featured the Rxivist preprint and written about our findings.
- 22 Jan 2019: Nature just published an article about Rxivist and our data.
- 13 Jan 2019: The Rxivist preprint is live!